79-17-4

Basic information

• Product Name: pimagedine
• Synonyms: pimagedine;Aminoguanidine mordant;1-Aminoguanidine;Aminate base;Amino(imino)methylhydrazine;N-Aminoguanidine;Aids030897;Aids-030897
• CAS NO: 79-17-4
• Molecular Formula: CH₆N₄
• Molecular Weight: 74.11
• EINECS: 201-183-1
• Product Categories: Pharmaceutical Intermediates
• Mol File: 79-17-4.mol
• Article Data: 14

Chemical Properties

• Melting Point: 182-185 °C (decomp)
• Boiling Point: 261.4oC at 760 mmHg
• Flash Point: 111.9oC
• Appearance: /
• Density: 1.72g/cm3
• Vapor Pressure: 0.0116mmHg at 25°C
• Refractive Index: 1.6660 (estimate)
• PKA: 11.08±0.70(Predicted)
• CAS DataBase Reference: pimagedine(CAS DataBase Reference)
• NIST Chemistry Reference: pimagedine(79-17-4)
• EPA Substance Registry System: pimagedine(79-17-4)

Safety Data

• Hazardous Substances Data: 79-17-4(Hazardous Substances Data)

Usage

Description

Pimagedine, a one-carbon compound, is unique in its structure, allowing it to act as a derivative of hydrazine, guanidine, or formamide. This distinctive characteristic makes it a versatile compound with potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
Pimagedine is used as a pharmaceutical compound for its ability to act as a derivative of hydrazine, guanidine, or formamide. Its unique structure allows it to be utilized in the development of drugs targeting specific conditions or diseases.
Used in Chemical Research:
In the field of chemical research, pimagedine is used as a one-carbon compound for studying its properties and potential reactions with other compounds. This can lead to the discovery of new chemical compounds and applications.
Used in Material Science:
Pimagedine's unique structure also makes it a candidate for use in material science, where it can be explored for its potential to create new materials or improve existing ones. Its ability to act as a derivative of hydrazine, guanidine, or formamide may contribute to the development of advanced materials with specific properties.
Overall, pimagedine's versatility and unique structure make it a valuable compound with potential applications in various industries, including pharmaceuticals, chemical research, and material science.

Enzyme inhibitor

This substituted hydrazine (FWhydrochloride = 110.55 g/mol; CAS 79-17-4), also named pimagedine, is a strong inhibitor of diamine oxidases as well as nitric oxide synthase. Note that aminoguanidine also inhibits the formation of advanced glycosylation end-products, reportedly by reacting with and trapping Amadori rearrangement-derived fragmentation products in solution. In view of this property, aminoguanidine has often been used to treat complications associated with chronic diabetes. Target(s): amine oxidase (copper-containing), or diamine oxidase; methylamine dehydrogenase; tryptophan tryptophylquinone enzymes; nitric-oxide synthase; b-fructofuranosidase, or invertase; monoamine oxidase, or amine oxidase; histidine decarboxylase; aldose reductase; catalase; formation of advanced glycosylation end products; adenosylmethionine decarboxylase; arginine deaminase; arginine kinase; aspartate aminotransferase; histamine N-methyltransferase.

InChI:InChI=1/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)

Upstream product

• 674-81-7 nitrosoguanidine 
• 556-88-7 nitroguanidine 
• 4353-48-4 -guanylhydrazon 
• 4362-82-7 Pinakolon-guanylhydrazon 
• 4364-72-1 N-<1-Methylpropylidenamino>-guanidin 
• 4364-76-5 2-cyclopentylidene-1-hydrazinecarboximidamide 
• 539-57-1 4-(1⁽²⁾H-tetrazol-5-yl)-tetraz-3-ene-1-carboximidic acid amide 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 
• 18264-75-0 3-amino-1-nitroguanidine 
• 7647-01-0 hydrogenchloride 
• 7664-41-7 ammonia 
• 64-19-7 acetic acid 
• 7803-57-8 hydrazine hydrate 

Downstream Products

• 61-82-5 3⁽⁵⁾-amino-1,2,4-triazole 
• 126937-28-8 (4-acetylamino-benzylidenamino)-guanidine 
• 37419-88-8 N-(5-phenyl-1H-[1,2,4]triazol-3-yl)-benzamide 
• 3679-92-3 N-(benzamido)-guanidine 
• 5373-68-2 5-amino-4-phenyl-2,4-dihydro-[1,2,4]triazolidine-3-thione 
• 86044-63-5 vanillylidenamino-guanidine 
• 42452-51-7 (E)-2-(2-methoxybenzylidene)hydrazine-1-carboximidamide 
• 6237-77-0 Glyoxylsaeure-guanylhydrazon 
• 5382-85-4 trans-cinnamylidenamino-guanidine 
• 27277-03-8 5-amino-3-hydroxymethyl-1H-1,2,4-triazole 
• 113038-69-0 2,2'-butanediyldioxy-di-benzaldehyde bis-carbamimidoylhydrazone 
• 118837-11-9 3,3'-dimethoxy-4,4'-pentanediyldioxy-di-benzaldehyde bis-carbamimidoylhydrazone 
• 122856-95-5 (4-nitro-benzenesulfonylamino)-guanidine 
• 122881-74-7 [(N-acetyl-sulfanilyl)-amino]-guanidine 

Relevant articles and documents

-

-

-

-

Microscale Parallel Synthesis of Acylated Aminotriazoles Enabling the Development of Factor XIIa and Thrombin Inhibitors

Herein we report a microscale parallel synthetic approach allowing for rapid access to libraries of N-acylated aminotriazoles and screening of their inhibitory activity against factor XIIa (FXIIa) and thrombin, which are targets for antithrombotic drugs. This approach, in combination with post-screening structure optimization, yielded a potent 7 nM inhibitor of FXIIa and a 25 nM thrombin inhibitor; both compounds showed no inhibition of the other tested serine proteases. Selected N-acylated aminotriazoles exhibited anticoagulant properties in vitro influencing the intrinsic blood coagulation pathway, but not extrinsic coagulation. Mechanistic studies of FXIIa inhibition suggested that synthesized N-acylated aminotriazoles are covalent inhibitors of FXIIa. These synthesized compounds may serve as a promising starting point for the development of novel antithrombotic drugs.

Glycation Cross-link Breakers to Increase Resistance to Enzymatic Degradation

The present invention relates to a method to treat a grafts, implant, scaffold, and constructs, including allografts, xenografts, autografts, and prosthetics comprising collagen, with an inhibitor of collagen cross-links and/or advanced glycation endproducts (AGE), in order to alleviate the mechanical weakness induced by the cross-links The invention also provides for kits for use in the operating theater during autograft, allograft or xenograft procedures, or for preparing allograft, xenografts or prosthetics that have not been already treated prior to packaging. The kit comprises a first agent or agents that inhibit collagen cross-links and/or advanced glycation endproducts, instructions for use, optionally a wash or rinse agent, and a device for containing the graft and first agent.